Management Forum courses now available at IPI Academy - visit IPI for an updated experience and a broader selection of courses and subjects
  • Home
  • Advanced Pharmacovigilance

Advanced Pharmacovigilance Training Course

This course will be of maximum benefit to those drug safety professionals who are working both in the clinical and post-marketing safety arena including QA for auditing.

1-3 Dec 2021

& 1-3 Mar 2022 , 7-9 Jun 2022 , 21-23 Sep 2022 , 7-9 Dec 2022

Book now

Details

Course overview

Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform. This three-day course is designed for those with at least two years’ knowledge in drug safety and will provide a comprehensive, yet practical assessment of the main regulations required to produce a compliant reporting company.

Key topics to be addressed:

  • Audits and expectations – risk-based inspections
  • Compliance and drug safety
  • Overview of the PSMF in the EU
  • Product safety reviews – purpose and function (incorporating the latest EU signal analysis requirements)
  • Safety reporting in licensing agreements
  • Developing company core safety information (CCSI) – CIOMS III
  • PSURs – timing, content and the DSUR and the latest ICH E2C (2nd revision requirements)
  • Implications for safety reporting in global clinical trials
  • Risk-benefit determinations
  • Risk management plans (RMPs)


By attending this event, you will:

  • Expand your global safety knowledge
  • Enhance your team’s capabilities and compliance in both the regulations and your company’s expectations
  • Help ensure you build and maintain a quality pharmacovigilance department ready for any pharmacovigilance inspection
  • Participate in group workshop sessions and discuss how to apply the legislation to ensure compliance, especially to satisfy regulatory inspections

Who should attend?

This course would be of maximum benefit to those safety professionals who are working both in the clinical and post–marketing safety arena including QA for auditing. The course covers very diverse activities within the safety department and would be advantageous to those who have either multifunction responsibilities or medical directors who manage teams in the various disciplines.

Programme

Due diligence

  • Due diligence on products/companies (partners and acquisitions)
  • Due diligence involvement – team composition
  • Safety information requirements for due diligence
  • Review of safety data (clinical and post-marketing)
  • Defining risk in due diligence appraisals

Training for drug safety reporting duties

  • Regulations concerning safety training
  • Who trains whom and when?
  • Training versus job description
  • Training records, maintenance and updates
  • Role of QA and HR in training

Audits and expectations

  • Regulatory expectations in pharmacovigilance audits (risk-based inspections)
  • Preparation for the audit
  • Records to be available at the audit
  • Audit findings/recommendations

Compliance and drug safety

  • Basic principles – what will the regulators want to see?
  • Measuring compliance
  • Quality versus quantity in safety reports
  • Future aspects in ensuring efficient compliance
  • Quality management under the new EU legislation

The PSMF

  • The PSMF – purpose and maintenance
  • The PSMF annexes
  • The PSMF and audits

Interactive exercise: The requirements for a safety department

Product safety reviews – purpose and function

  • The Safety Review Committee (SRC)
  • What to look for in signal evaluation under latest EU guidance
  • Timings for safety review in clinical and post-marketed products
  • Record keeping for safety review meetings
  • Serious safety findings – crisis management following new safety findings

Interactive exercise: Designing the requirements for a safety review group

Safety reporting in licensing agreements

  • What types of licensing agreements exist?
  • What are the EU and FDA regulations concerning licensing agreements?
  • Audits of pharmacovigilance capabilities in licensing partners
  • What agreements need to be in place for safety reporting?
  • Safety reporting agreements – what needs to be covered?
  • Monitoring safety agreements – what happens if it goes wrong?

Developing CCSI – CIOMS III

  • CIOMS III and CCSI
  • Developmental core safety information (DCSI)
  • How to determine what to include and what to exclude in DCSI/CCSI
  • Are there differences in EU and FDA?
  • Maintenance and development of CCSI

Interactive exercise: Should new safety data from a clinical trial be put into core safety information?

PSURs and the revisions in ICH E2C

  • Timing for PSURs
  • PSUR content and latest format
  • Late breaking information and PSUR extensions
  • The DSUR

The EU Clinical Trials Directive

  • The principles of the Directive
  • Implications for safety reporting in global clinical trials
  • The SUSAR database
  • The EUDRACT database
  • The new EU Clinical Trial Regulation

Risk-benefit determinations

  • Definitions of risk-benefit – FDA and EU perspective
  • Risk-benefit assessments – who does this and where does the information go?
  • Safety assessments and risk-benefit – frequency and reporting
  • Changes in risk-benefit – how to manage and review existing profiles

Interactive exercise: Reviewing the safety and risk-benefit of a product

RMPs

  • Purpose
  • Content
  • Monitoring and updating the RMP
  • Reporting the RMP

Crisis management within drug safety

  • Regulations and guidelines in connection with serious safety issues
  • What determines a crisis?
  • Communications to regulators – what is required?
  • Communications within the company
  • What happens next?

Interactive exercise: Deciding how to handle a major crisis within the company

Delegates will be split into groups and present what they need to have in place in order to effectively manage the crisis and look to its resolution.


Presenter

Graeme Ladds (More...)

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

Book now

Book now

1-3 Dec 2021
Face-to-face, (venue not yet confirmed)
1-3 Dec 2021
Face-to-face
(venue not yet confirmed)
GBP 1,849 1,549
EUR 2,589 2,169
USD 2,884 2,416
Until 27 Oct*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy
1-3 Mar 2022
Live webinar
1-3 Mar 2022
Live webinar
GBP 1,549 1,249
EUR 2,229 1,809
USD 2,524 2,056
Until 25 Jan 22*
Enrol now
to attend
Live webinar
7-9 Jun 2022
Face-to-face, (venue not yet confirmed)
7-9 Jun 2022
Face-to-face
(venue not yet confirmed)
GBP 1,849 1,549
EUR 2,589 2,169
USD 2,884 2,416
Until 3 May 22*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy
21-23 Sep 2022
Live webinar
21-23 Sep 2022
Live webinar
GBP 1,549 1,249
EUR 2,229 1,809
USD 2,524 2,056
Until 17 Aug 22*
Enrol now
to attend
Live webinar
7-9 Dec 2022
Face-to-face, (venue not yet confirmed)
7-9 Dec 2022
Face-to-face
(venue not yet confirmed)
GBP 1,849 1,549
EUR 2,589 2,169
USD 2,884 2,416
Until 2 Nov 22*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code

Continuing professional development

This course qualifies for 18 hours for your CPD records.
More about CPD

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Astellas BV
  • AstraZeneca
  • AstraZeneca AB
  • Baxter AG
  • Bayer Animal Health GmbH
  • Bayer Turk Kimya San. Ltd. Sti
  • Berlin-Chemie AG
  • Boehringer Ingelheim France
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Dexcel Pharma Limited
  • Dong-A ST Co.,Ltd
  • Eisai Limited
  • Ewopharma International s.r.o.
  • Forest Laboratories UK Ltd
  • Hoffmann-La Roche Incorporated
  • Klifo
  • Kowa Research Europe Ltd
  • Medivation
  • Merck Serono
  • Mundipharma Research GmbH & Co Kg
  • Norgine Ltd
  • Novo Nordisk
  • Orphan Europe
  • PharmaChem Consulting
  • Procter & Gamble Pharmaceuticals
  • Ranbaxy Laboratories Ltd
  • Sanofi-aventis AB
  • SEQ Limited
  • TFS, trial form support
  • UCB Pharma Limited

Really good speaker, lots of examples of scenarios which helps. Allowed interaction between the delegates to discuss topics during exercises.

Rebecca Brennan, Safety Advisor, Alliance Healthcare Ltd, Mar 21

Very good webinar. Well structured, interactive questions, small group, advanced topics (not easy to find elsewhere), competent speaker, good platform.

Bettina Isler, Medical Information Manager, OrPha Swiss GmbH, Mar 21

Inspiring speaker. I was very excited about all the anecdotes that he told.
Overall a very rewarding course.

Helle Ribjerg, Global Safety Specialist, LEO Pharma, Mar 21

Great

Sidse Schjøtz, Complinace Manager, ALK , Sep 20

Generally very good and good to have the anecdotes from real life.

Sanne Mathias, Head of Compliance, ALK , Sep 20

Good course and the leader was very clear in what he wanted to say. Exercises were fun..

Amrita Kang, drug safety scientist, GE healthcare, Sep 20

Parts of the presentation especially Day 3 were informative as it was more tailored to my role. I enjoyed the talk of RMPs, PSURs and crisis management. A lot of basics however were covered in this 'advanced course' in the CT directive topic, would be nice just to state what's changed and what's not changed almost like presenting a gap analysis, instead of covering basic definitions such as definition of an SAE and SUSAR and investigator reporting timelines. There was a 2 minute discussion on Brexit related changes on Day 2 which could have been a formal session as a presentation as I found that very useful for my role.

Maria Sajid, Safety Evaluation Scientist, Eisai Europe Ltd, Sep 20

Very nice course - will recommend to colleagues

Tina Rishoej Clausen, Global Safety Specialist, LEO Pharma, Sep 20

I was hoping to get more knowledge about the topics listed in the course presentation and I actually got a lot more, as we were not only given information related to the legislation in force but also very useful examples of applicability and some non-compliance cases. The speaker is undoubtedly an expert in the field with excellent presentation skills of all the proposed topics, including the most complex ones from a regulatory point of view. His experience and his analytic method facilitated my understanding of some critical passages of the law.

Ilaria Gargano, Global Safety Specialist, Leo Pharma, Sep 19

[Graeme] was a very good presenter with very good industry knowledge and experience. Very interactive sessions and answered all our questions.

Smitha Bhat, Principal CMG Scientist, GlaxoSmithKline, Sep 19

The speaker was able to make a dry topic really exciting and I particularly liked the interaction with the group.

Margot Börgartz, Stewardship Manager, Bayer AG, Sep 19

Overall, the best seminar I've attended in format, topics, and speaker. I had hoped to learn about PV in general and all the different reporting requirements and report types – I learned much more than that. The speaker was great and I particularly liked the real-life stories and examples.

Jane Bateman, Senior Drug Safety Scientist, GE Healthcare, Sep 19

Graeme has superb knowledge of the regulations and guidelines around pharmacovigilance and talks in a passionate and engaging manner. An excellent course that really gives the students a much better understanding of pharmacovigilance and the opportunity to share knowledge. The content was spot on and Graeme's presentation style was engaging.

Christopher Harper, Senior Medical Information Manager, Astellas Pharma Europe Ltd, Mar 19

Great presentations, great time keeping, good balance between exercises and presentations

Ida Mizera, Local Responsible Person for PV, Grunenthal Ltd, Mar 19

The content of the course was excellent for an all round view of PV, the presentations were good and flowed from one aspect of PV to another. Graeme's passion and energy for drug safety was evident throughout the three days. I really enjoyed this course.

Ciara Walsh, Head of Regulatory Affairs and Pharmacovigilance, Noden Pharma DAC, Mar 19